Home › Tarix Granted Orphan Drug Status For TXA127
 

Keywords :   


Tarix Granted Orphan Drug Status For TXA127

2016-02-18 02:28:07| drugdiscoveryonline News Articles

Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted Orphan Drug status to the company's lead compound, TXA127, for the treatment of laminin-deficient congenital muscular dystrophy (LAMA2 MD or MDC1A). Early-onset LAMA2-related muscular dystrophy occurs in approximately 1 in 30,000 individuals and accounts for between 30 and 40 percent of total cases of congenital muscular dystrophy.

Tags: status drug granted orphan

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05Farm Progress America, May 20, 2024
20.05Farm Progress America, May 20, 2024
20.05Nielsen launches The Media Distributor Gauge
20.05Minerva AI Companion enhances the TV viewing experience
20.05Ryanair profits surge after fares climb by 20%
20.05SES Ethiosat delivering content to 95% of TV homes in Ethiopia
More »